Corticosteroid implants for chronic non-infectious uveitis

被引:43
作者
Brady, Christopher J. [1 ]
Villanti, Andrea C. [2 ]
Law, Hua Andrew [3 ]
Rahimy, Ehsan [4 ]
Reddy, Rahul [5 ]
Sieving, Pamela C. [6 ]
Garg, Sunir J. [4 ]
Tang, Johnny [7 ]
机构
[1] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[4] Thomas Jefferson Univ, Retina Serv Wills Eye Hosp, MidAtlantic Retina, Philadelphia, PA 19107 USA
[5] Associated Retinal Consultants, Phoenix, AZ USA
[6] Natl Inst Hlth Lib, Bethesda, MD USA
[7] Case Western Reserve Univ, Univ Hosp Eye Inst, Cleveland, OH 44106 USA
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2016年 / 02期
基金
美国国家卫生研究院;
关键词
FLUOCINOLONE ACETONIDE IMPLANT; DEXAMETHASONE INTRAVITREAL IMPLANT; STEROID-TREATMENT; INTRAOCULAR-PRESSURE; POSTERIOR UVEITIS; SUSTAINED-RELEASE; TRIAL; INTERMEDIATE; RETISERT; DELIVERY;
D O I
10.1002/14651858.CD010469.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Uveitis is a termused to describe a heterogeneous group of intraocular inflammatory diseases of the anterior, intermediate, and posterior uveal tract (iris, ciliary body, choroid). Uveitis is the fifth most common cause of vision loss in high-income countries, accounting for 5% to 20% of legal blindness, with the highest incidence of disease in the working-age population. Corticosteroids are the mainstay of acute treatment for all anatomical subtypes of non-infectious uveitis and can be administered orally, topically with drops or ointments, by periocular (around the eye) or intravitreal (inside the eye) injection, or by surgical implantation. Objectives To determine the efficacy and safety of steroid implants in people with chronic non-infectious posterior uveitis, intermediate uveitis, and panuveitis. Search methods We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (Issue 10, 2015), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to November 2015), EMBASE (January 1980 to November 2015), PubMed (1948 to November 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to November 2015), the metaRegister of Controlled Trials (mRCT) (www.controlledtrials.com) (last searched 15 April 2013), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health Organization (WHO) InternationalClinical TrialsRegistry Platform(ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic search for studies. We last searched the electronic databases on 6 November 2015. We also searched reference lists of included study reports, citation databases, and abstracts and clinical study presentations from professional meetings. Selection criteria We included randomized controlled trials comparing either fluocinolone acetonide (FA) or dexamethasone intravitreal implants with standard-of-care therapy with at least six months of follow-up after treatment. We included studies that enrolled participants of all ages who had chronic non-infectious posterior uveitis, intermediate uveitis, or panuveitis with vision that was better than hand-motion. Data collection and analysis Two review authors independently reviewed studies for inclusion. Two review authors independently extracted data and assessed the risk of bias for each study. Main results We included data from two studies (619 eyes of 401 participants) that compared FA implants with standard-of-care therapy. Both studies used similar standard-of-care therapy that included administration of prednisolone and, if needed, immunosuppressive agents. The studies included participants from Australia, France, Germany, Israel, Italy, Portugal, Saudi Arabia, Spain, Switzerland, Turkey, the United Kingdom, and the United States. We assessed both studies at high risk of performance and detection bias. Only one study reported our primary outcome, recurrence of uveitis at any point during the study through 24 months. The evidence, judged as moderate-quality, showed that a FA implant probably prevents recurrence of uveitis compared with standard-of-care therapy (risk ratio (RR) 0.29, 95% confidence interval (CI) 0.14 to 0.59; 132 eyes). Both studies reported safety outcomes, and moderatequality evidence showed increased risks of needing cataract surgery (RR 2.98, 95% CI 2.33 to 3.79; 371 eyes) and surgery to lower intraocular pressure (RR 7.48, 95% CI 3.94 to 14.19; 599 eyes) in the implant group compared with standard-of-care therapy through two years of follow-up. No studies compared dexamethasone implants with standard-of-care therapy. Authors' conclusions After considering both benefits and harms reported from two studies in which corticosteroids implants were compared with standardof- care therapy, we are unable to conclude that the implants are superior to traditional systemic therapy for the treatment of noninfectious uveitis. These studies exhibited heterogeneity in design and outcomes that measured efficacy. Pooled findings regarding safety outcomes suggest increased risks of post-implant surgery for cataract and high intraocular pressure compared with standard-of-care therapy.
引用
收藏
页数:47
相关论文
共 67 条
[1]   Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries [J].
Abba, Katharine ;
Deeks, Jonathan J. ;
Olliaro, Piero ;
Naing, Cho-Min ;
Jackson, Sally M. ;
Takwoingi, Yemisi ;
Donegan, Sarah ;
Garner, Paul .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (07)
[2]  
Acharya Nisha, 2004, International Ophthalmology Clinics, V44, P33, DOI 10.1097/00004397-200404430-00006
[3]  
[Anonymous], 1995, Treat Rev, P4
[4]  
[Anonymous], OPHTHALMOLOGY
[5]  
[Anonymous], 2011, COCHRANE HDB SYSTEMA
[6]  
[Anonymous], 2014, COCHR COLL REV MAN R
[7]   Proof of Concept for Combined Insertion of Fluocinolone Acetonide and Glaucoma Drainage Implants for Eyes with Uveitis and Glaucoma [J].
Ansari, Husam ;
Kempen, John H. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 149 (05) :699-700
[8]   A Comparison Between the Fluocinolone Acetonide (Retisert) and Dexamethasone (Ozurdex) Intravitreal Implants in Uveitis [J].
Arcinue, Cheryl A. ;
Ceron, Olga M. ;
Foster, C. Stephen .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (05) :501-507
[9]   Intraocular Pressure Outcome of Patients with Fluocinolone Acetonide Intravitreal Implant for Noninfectious Uveitis [J].
Bollinger, Kathryn ;
Kim, James ;
Lowder, Careen Y. ;
Kaiser, Peter K. ;
Smith, Scott D. .
OPHTHALMOLOGY, 2011, 118 (10) :1927-1931
[10]   Prevalence and management of elevated intralocular pressure after placement of an intravitreal sustained-release steroid implant [J].
Bollinger, Kathryn E. ;
Smith, Scott D. .
CURRENT OPINION IN OPHTHALMOLOGY, 2009, 20 (02) :99-103